# V1 Empirics Check — x-ai/grok-4.1-fast (Variant B)

**Model:** x-ai/grok-4.1-fast
**Variant:** B
**Date:** 2026-03-31T10:44:21.478873

---

### 1. Idea Fidelity
The paper faithfully pursues the original idea manifest. It uses the exact five staggered state bans (IN/WI 2014, AR 2015, AL 2016, RI 2017), CDC VSRR state-month data (2015-2025) with drug-type decomposition (opioids, synthetics, heroin, psychostimulants as negative control), and Callaway-Sant'Anna (2021) staggered DiD as the primary estimator, supplemented by TWFE and robustness checks (wild cluster bootstrap, randomization inference). The research question—whether bans increased opioid mortality via substitution—is directly tested, with psychostimulants/cocaine as falsification and a mechanism test via decomposition. No key elements are missed; the null finding (rather than expected positive effect) emerges organically from the data.

### 2. Summary
This paper provides the first causal evidence on state kratom bans (2014-2017), exploiting staggered adoption in a DiD framework with CDC provisional overdose death data. It finds a precise null effect on all-drug and opioid mortality (C-S ATT = 0.043 log points, SE = 0.042), with drug-type decompositions and triple differences ruling out substitution toward fentanyl or other opioids (symmetric negative TWFE coefficients across categories, DDD = -0.117, p=0.084). The results challenge the substitution hypothesis, attributing TWFE biases to differential trends in smaller ban states, and inform debates on prohibition versus regulation.

### 3. Essential Points
1. **Pre-trend validation is asserted but not visually or quantitatively demonstrated in detail.** The text mentions a Sun-Abraham event-study pre-trend coefficient of 0.054 (event time -2) but provides no figure or full dynamic coefficients table for C-S or TWFE event studies. Readers cannot assess parallel trends without this; include graphical event-study plots (e.g., C-S group-time averages) and joint pre-trend tests (e.g., via \texttt{eventstudyinteract} or CS diagnostics) as a prerequisite for credibility.

2. **Limited effective sample for C-S estimator undermines power claims.** Only three states (AR, AL, RI) have clean pre-periods, excluding WI/IN (always-treated post-2015), reducing treated variation and precision (wide CI: ±20%). The "well-powered null" claim requires formal power calculations (e.g., minimum detectable effect sizes via simulations, accounting for cluster size and serial correlation in 12-month rolling data); current robustness (e.g., wild bootstrap CI -6.7 to +5.4 log points) highlights low power for small effects, which must be explicitly quantified.

3. **Data suppression and exclusion bias toward larger states.** Excluding 8 jurisdictions (including some neighbors like FL, LA) for >50% suppression, while retaining ban states AL/AR with 33-38% missing opioid data, risks selection bias. Sensitivity to alternative suppression thresholds (e.g., 30%) or imputation (e.g., multiple imputation for small cells) is needed; clarify if exclusions correlate with treatment (e.g., via balance table on observables).

### 4. Suggestions
The paper is coherent, novel (truly zero prior causal lit), and data quality is high (public CDC VSRR, transparent construction, ~6k obs). The null conclusion is well-supported by C-S, decomposition rejecting substitution (strong mechanism test), and robustness to inference methods—ruling out large effects despite power limits. To elevate to AER:Insights polish:

- **Figures for transparency and intuition (priority).** Add 2-3 event-study plots: (i) C-S dynamic ATT by event time for all-drug OD (with 95% CIs from wild bootstrap); (ii) TWFE event study for opioid vs. psychostimulant deaths; (iii) synthetic control-style trajectory plot comparing ban states to controls (using \texttt{gsynth} or SCM with state-month data). These visualize pre-trends, post-dynamics, and symmetric negatives, making the "confounding trajectory" argument intuitive.

- **Expand robustness suite.** (i) Annual aggregation to mitigate 12-month rolling serial correlation (aligns with C-S annual frequency; compare monthly vs. annual C-S). (ii) Neighbor-only controls expanded to synthetic controls weighted by pre-trends (e.g., \texttt{Synth} package matching on opioid/synthetic rates 2015-2016). (iii) Placebo outcomes fully implemented: extend Table 1 to heart disease/cancer (NCHS quarterly data pre-2015) with C-S estimates. (iv) Heterogeneity by state size/population (e.g., interact ban with log(pop); smaller ban states drive negatives).

- **Mechanism deepening.** Build on DDD: estimate quadruple differences (e.g., synthetic opioids × ban × post, vs. psychostimulants) or pathway models (e.g., shift-share where treatment intensity proxies kratom prevalence via Google Trends "kratom" searches state-month, pre-ban). Link to user surveys: regress ban effects heterogeneous by pre-ban opioid burden (e.g., split median 2015 opioid rate).

- **Power and bounds.** Compute minimum detectable effects (MDEs) explicitly: e.g., for C-S, simulate under null with observed residuals/SEs, targeting 80% power at α=0.05 (expect MDE ~0.15-0.20 log points given 3 clusters). Present fuzzy bounds assuming partial enforcement (e.g., instrument ban by distance to online vendors or post-ban Google Trends drop).

- **Discussion enhancements.** (i) Quantify ecological fallacy: back-of-envelope calc (1-2% prevalence × 20% OD risk hike = ~10-20 extra deaths/state-year) vs. SD(noise) ~hundreds; cite for individual data needs. (ii) Contrast cannabis lit more sharply: table comparing effect sizes/MDEs across studies (kratom null vs. cannabis -0.10 to -0.20 log points). (iii) Policy appendix: timeline of KCPAs (post-2019) as "reverse treatment" for future work, with teaser DiD (no bans vs. KCPAs).

- **Presentation tweaks.** (i) Table 1: add pre/post means by treatment (not just totals) and balance stats (e.g., t-tests on 2015 covariates: pop, income, pre-OD rates, other policies like PDMPs). (ii) Table 2: include C-S event-time coeffs; move SDE table to main text as it crisply shows "large negative" confounders. (iii) Abstract: specify CI explicitly ("rules out >20% increase"). (iv) Extend pre-2015 via NCHS (manifest mentions 1999-2015 rates): merge for TWFE pre-2015, test trends.

- **Minor:** Fix Table 4 LOO (missing RI row explanation in notes); cite R packages (e.g., \texttt{csdid} for C-S); add GitHub repro code link.

These changes (~70% empirical polish) would make this a strong candidate: novel policy, clean ID, supported null with mechanism falsification. Reject threshold unmet; revise and resubmit.
